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Loperamide for treatment·
of acute diarrhoea in
infants and young children
A double-blind placebo-controlled trial
Malcolm D. Bowie, Ivor D. Hill, Michael D. Mann
High-dose loperamide reduces stool output and shortens
the duration of diarrhoea in infants receiving intravenous
fluids for rehydration, but may cause potentially harmful
side-effects in a small number of patients. This double-
blind placebo-controlled study was undertaken to assess
whether loperamide would shorten the hospital stay of
dehydrated children in a rehydration unit. Ninety-one
patients with acute dehydrating diarrhoea received
loperamide and 94 received placebo. The groups were
clinically indistinguishable on admission to hospital. There
was no difference between groups for the duration of
rehydration or the number of treatment failures. The use of
loperamide is not recommended in the treatment of infants
and young children with acute diarrhoea.
S Afr Med J 1995; 85: 885-887.
Loperamide in higher than recommended doses reduces
stool output and duration of acute diarrhoea in infants
receiving intravenous fluids for rehydration.' Although there
are concerns about the safety of loperamide when given to
children,2-4 particularly those less than 3 months of age,' it is
a potentially u~eful agent in developing countries where
large numbers of children require admission to rehydration
units for treatment of dehydration due to diarrhoeal disease.
During the seasonal summer peaks of incidence, these units
become seriously overcrowded and any treatment modality
that can effectively and safely shorten the time patients have
to be kept in the unit would be of benefit.
This study was designed to assess the role of high-dose
loperamide in the management of infants and young children
with acute diarrhoea associated with mild-to-moderate
dehydration. All were ·rehydrated with enterally administered
glucose electrolyte solutions. The effect of loperamide on
the duration of admission to the rehydration unit was
compared with that of placebo given to a similar group of
patients in a double-blind fashion.
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Patients between 3 and 18 months of age requiring
admission to hospital for treatment of acute dehydrating
diarrhoeal disease were assessed. Those who were clinically
shocked, had an ileus, required antibiotics for other
systemic illness (e.g. pneumonia, septicaemia), had
dysentery (blood and pus in their stools) or features of
kwashiorkor or marasmus were excluded. Informed consent
for inclusion in the trial was obtained from the parent or legal
guardian. The study was approved by the Ethical Review
Committee of the University of Cape Town.
The patients were weighed on admission and at least
twice daily thereafter until discharge. Serum acid base
status, electrolyte and blood urea nitrogen values were
determined on entry into the study and thereafter when
clinically indicated. The first stool sample passed after
admission was tested for rotavirus and cultured for
Salmonella, Shigella and Campylobacter. Duration of
diarrhoea prior to initiation of treatment was recorded, as
was the exact time of admission to, and discharge from, the
hospital.
Fluid therapy was the same in all cases. Milk feeds were
initially withheld and rehydration commenced with
continuous nasogastric tube infusion of a glucose electrolyte
solution containing Na" 64 mmol/I, CI- 54 mmol/I, K+ 20
mmol/I, HC03- 30 mmol/I and glucose 111 mmol/l. The
volume of fluid administered during the first 24 hours was
that calculated to correct the clinical degree of dehydration
(i.e. 50 ml/kg if 5% and 100 ml/kg if 10% dehydrated), plus
the amount needed to provide a maintenance volume of
150 ml/kg/day. In children over 12 months the maintenance
volume was reduced to 100 ml/kg/day. Patients were
reassessed at 4-hourly intervals until fUlly rehydrated. On
each occasion fluid requirements were recalculated based
on the clinical signs of dehydration and change in body
weight since admission. Provided the patient had improved
clinically, full-strength formula milk feeds were reintroduced
6 - 12 hours after admission. The volume of milk given was
calculated to provide 100 - 150 ml/kg/day in 8 equally
divided amounts depending on_age. With the introduction of
formula feeds, the volume of glucose electrolyte solution
was adjusted accordingly to replace the ongoing abnormal
losses in the stools and maintain hydration.
On admission patients were assigned to receive either
loperamide or placebo in a double-blind fashion;
sequentially numbered bottles were prepared by the
manufacturer (Janssen Pharmaceutical. A sealed copy of the
code for the numbered bottles was kept by a hospital
administrator who was not directly involved in the
investigation. In the event of a possible adverse drug
reaction to loperamide, the administrator would reveal the
contents of only that particular patient's numbered bottle to
the investigators. The amount of medication given was
designed to provide 0,8 ml/kg/day of loperamide. This was
administered in 3 equally divided doses at 8-hourly intervals
to a maximum of 6 doses. The infants were deemed fit for
discharge not when diarrhoea had ceased but as soon as
they were clinically hydrated, were taking oral feeds
satisfactorily and were able to maintain their rehydrated
body weight without needing additional glucose electrolyte
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Table I. Medians (ranges) of the clinical parameters and duration
of hospital stay for patients receiving loperamide or placebo
Acute diarrhoea is usually a self-limiting illness and
the use of antidiarrhoeal agents in paediatric practice is
controversial. Some have never been shown to be effective
while others have unacceptable side-effects."tO Loperamide
is an antidiarrhoeal drug that is said to have antisecretory
action on the gut and to be relatively free of side-effects."·13
Studies using the recommended doses have failed to show
any clear benefit of loperamide over placebo, '4,'5 but others
using much higher doses claimed it was effective for treating
both acute and chronic diarrhoea in children''''· and that it
affected the overall recovery rate beneficially. Recently we
demonstrated that loperamide in a dose of 0,8 mg/kg/day
(i.e. four times the recommended dose) significantly
decreased stool output and duration of diarrhoea in infants
with acute diarrhoea who received intravenous fluids for
rehydration.' The drug may have been the cause of side-
effects in a small number of patients, particularly in very
young infants. For this reason we cautioned against the
indiscriminate use of loperamide and recommended that it
be aV~ided in those with mild diarrhoea who do not need
hospitalisation for treatment of dehydration, and in very
young infants.
The demonstrated effect of loperamide on stool volume of
intravenously rehydrated patients led us to question whether
the drug would be a c1inicaily useful adjunct to fluid therapy
if used under supervision in a hospital rehydration unit. By
decreasing stool output, infants and children might require
less additional fluid and a shorter stay in the unit. This in
turn would greatly alleviate the problem of overcrowding
during the peak of the diarrhoea season.
The sole criterion used in this study was duration of stay
in the rehydration unit. Standard procedure is that patients
are discharged from the unit once they can be satisfactorily
and safely treated as outpatients, i.e. are clinically hydrated,
taking oral feeds satisfactorily and are able to maintain their
rehydrated body weight without needing additional glucose
electrolyte solution. Most still have diarrhoea. Patients
receiving loperamide were clinically indistinguishable from
solution. They were then followed on an outpatient basis to
check continuing improvement. If they were discharged
before all 6 doses of medication had been administered, the
drug was discontinued. Treatment was considered to have
failed when children required glucose electrolyte solution to
maintain hydration for more than 72 hours or if they
developed severe persistent vomiting or an ileus. Thereafter,
such patients were managed according to the usual protocol
used at Red Cross Children's Hospital.5
The actual percentage dehydration on admission was
determined in retrospect from the difference between the
admission and fully rehydrated weights. The nutritional
status of each patient was assessed by expression of the
rehydrated weight as a percentage of expected weight-for-
age, as per the NCHS centiles. The number of treatment
failures in each group was recorded, and the duration of
hospitalisation for those who responded to treatment was
calculated from the admission and discharge times.
The trial was terminated after 200 patients had been
recruited. Thereafter the treatment code was broken and the
patients were assigned either to the loperamide or placebo
group for comparison. The groups were compared in
respect of stool pathogens, age, percentage expected
weight-for-age, duration of diarrhoea prior to admission,
duration of hospitalisation for those who responded to
treatment, the number of doses of medication administered
before discharge and the number of treatment failures. The
Mann-Whitney U test was used in all comparisons.
Results
Fifteen patients were not included in the final analysis
because of incomplete data collection (N = 5), incorrect
medication dose given (N = 5), development of clinically
suspected septicaemia (N = 4) and febrile seizures (N = 1).
Of the 185 who completed the study, 91 received
loperamide and 94 received placebo. There was no
difference between the two groups with regard to stool
pathogens. In approximately 50% no pathogen was
identified, and in both groups about 25% had rotavirus, 15%
had Campylobacter and 10% had Salmonella. The medians
and ranges for age, percentage expected weight for age,
duration of diarrhoea prior to admission, calculated
percentage dehydration on admission, duration of
hospitalisation and number of medication doses
administered for both groups are shown in Table I. There
were no significant differences between the groups in
respect of any of these parameters. Twelve patients in the
loperamide group and 10 in the placebo group failed
treatment and still required additional fluids to maintain
hydration after 72 hours in hospital. Persistent vomiting or
ileus did not occur in any patient. Those who failed
treatment did not differ from others within their respective
groups with regard to age, percentage expected weight for
age, duration of diarrhoea prior to admission and calculated
percentage dehydration.
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those receiving placebo and the double-blind nature of the
.trial ensured there was no bias towards one group in
decisions about individual patients' discharge. The mean
duration of stay for the two groups was almost identical and
the majority of children were discharged in less than 72
hours. Treatment failure occured in 13% of the loperamide
group and 10% of the placebo group, figures similar to
those reported elsewhere for delayed recovery from acute
diarrhoea in infants. '920 No beneficial effect in shortening of
the stay or reduction of numbers of those requiring
prolonged treatment in the rehydration unit was noted.
It is not possible to compare the results of this with our
previous study' as completely different end-points were
used as criteria of efficacy of loperamide. No adverse effects
were noted in any patient receiving loperamide during this
study, but infants under 3 months of age were excluded. It
was in this age group that a temporal relationship of
drowsiness and loperamide administration was noted in the
previous study.' However, as no practical beneficial effect
could be demonstrated at a unit for the mass rehydration of
infants dehydrated due to diarrhoeal disease, and given our
and others' previous experience"3 of potentially dangerous
side-effects, the use of loperamide is not recommended.
We thank Janssen Pharmaceutica for finanCial support and
supplies of loperamide and placebo.
REFERENCES
1. Motala e, Hill 10, Mann MO, Bowie MD. Effect of loperamide on stool output and
duration of acute infectious diarrhoea in infants. J Pediatr 1990; 117: 467-471.
2. Bhutta TI, Tahir KI. Loperamide poisoning in children (Letter). Lancet 1990; 335:
363.
3. Schwartz RH, Rodriguez WJ. Toxic delirium possibly caused by loperamide
(Letter). J Pediatr 1991; 118: 656-657.
4. Ahmad SR. Lomotil overdose (Letter). Pediatrics 1992; 89: 980.
5. Bowie MD, Hill ID. Management of persistent diarrhea in infants. Indian J Pediatr
1987; 54: 475-480.
6. Alestig K, Trollfors 8, Stenqvist K. Acute non specific diarrhoea studies on the
use of charcoal, kaolin-pectin and diphenoxylate. Practitioner 1979; 222: 859-
862.
7. Portnoy Bl, Du Pont Hl, Pruitt D, Abdo JA, Rodriguez JT. Antidiarrheal agents in
the treatment of acute diarrhea in children. JAMA 1976; 236: 844-846.
8. Harries JT, Rossiter M. Fatal lomotil poisoning (Letter). Lancet 1969; 1: 150.
9. Bargman GJ, Gardner L1. Near fatality in an infant following 'lomotil' poisoning.
Pediatrics 1969; 44: 770-771.
10. Rosenton G, Freeman M, Standard Al, Weston N. Warning: use of Lomotil in
children. Pediatrics 1973; 51: 132-134.
11. Sandhu B, Tripp JH, Candy DCA, Harries JT. Loperamide inhibits cholera toxin-
induced small intestinal secretion. Lancet 1979; 2: 689-690.
12. Hardcastle J, Hardcastle PT, Read NW, Redfern JS. The action of loperamide in
inhibiting prostoglandin-induced secretion in the rat. Br J Pharmacal 1981; 74:
563-569.
13. Hughes S, Higgs NB, Turnberg LA. Anti-diarrhoeal activity of loperamide; studies
of its influence on ion transport across rabbit ileal mucosa in vitro. Gut 1982; 23:
974-979.
14. Owens JR, Broadhead A, Hendrickse RG, Jaswal OP, Gangal RN. Loperamide in
the treatment of acute gastro-enteritis in early childhood: ·report on a two centre
double-blind controlled trial. Ann Trop Paediatr 1981; 1: 135-141.
15. Kassem AS, Madkour AB-S, Massoub BZ, Mehanna ZB. Loperamide in acute
childhood diarrhoea: a double blind controlled trial. J Diarrhoeal Dis Res 1983; 1:
10-16.
16. Sandhu BK, Tripp JH, Milia PJ, Harries JT. loperamide in severe protracted
diarrhoea. Arch Dis Child 1983; 58: 39-43.
17. Diarrhoeal Disease StUdy Group (UK). Loperamide in acute diarrhoea in
childhood: results of a double blind placebo controlled multi-centre clinical trial.
BMJ 1984; 289: 1263-1267.
18. Karrar ZA, Abdulla MA, Moody JB, MacFarlane SBJ, Albwardy M, Hendrickse RG.
Loperamide in acute diarrhoea in childhood: results of a double blind placebo
controlled clinical trial. Ann Trap Paediatr 1987; 7: 122-127.·
19. Gribbin M, Walker-Smith JA, Woods CBS. Delayed recovery following acute
gastroenteritis. Acta Paediatr 8elg 1976; 29: 167-171.
20. Brown KH, Black RE. Idiopathic prolonged diarrhea. In: Walker WA, Durie PR,
Hamilton JR, Walker-Smith JA, Watkins JB, eds. Pediatric Gastrointestinal
Disease. Philadelphia: e.C. Decker Inc., 1991; 733-736.




infection in a paediatric
hospital by RNA
electrophoresis
P. Bos, M. Kirsten, R. E. Cronje, A. D. Steele
During the spring of 1987 and the autumn of 1988, stool
specimens were collected from infants and young children
in the paediatric unit at H. F. Verwoerd Hospital, Pretoria,
and examined for the presence of rotaviruses to assess
the potential for hospital-acquired infection in the
paediatric wards. Stool samples were also collected from
children admitted to the hospital for causes unrelated to
gastro-enteritis to investigate the possible asymptomatic
carriage of rotavirus in this population. Hospital-acquired
rotavirus infection was detennined in only 9% of cases.
Very little asymptomatic carriage of the virus was
identified. Electrophoretic analysis of the rotavirus strains
showed that the majority of the infections (20 of 42) were
associated with a particular strain with a long RNA profile,
while 7 minor strains co-circulated (5 with a long
electrophoretype and 2 with a short one). An apparent
small outbreak of nosocomial infection with a single strain
was observed to occur in one of the paediatric wards
during the spring and early summer.
S Atr Med J 1995; 85: 887-891.
Rotavirus is well known as an important cause of acute
infantile gastro-enteritis resulting in the hospitalisation of
young children with the infection.' However, the virus has
also been reported to be a leading cause of nosocomial
infection, especially in newborn nurseries2.3and paediatric
units.4" Recent reports have highlighted the tremendous
impact of nosocomial infection with diarrhoeal agents,
causing an inestimable increase in morbidity, a potential
increase in infant mortality and a significant increase in
hospital costs.""
Rotavirus is ideally suited to spread in the hospital setting
owing to: (I) the large numbers of infectious particles
excreted in the stools of infected individuals, '.9 (il) the low
infectious dose of virus;4.'o (HI) the resistance of rotavirus to
commonly used disinfectants;",'2 (iv) the often asymptomatic
carriage of the virus.;13·14 (v) the ability of the virus to remain
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